Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16840715 | 0.57 | CCND3 (0.50) | HTR3AADRA2CKDM4EGAAMAPT | |
| SCHEMBL12190706 | 0.56 | MAPT (0.63) | HTR3AADRA2CKDM4EGAAMAPT | |
| SCHEMBL2264251 | 0.56 | ADRA2C (0.59) | ADRA2CKDM4EGAAMAPTPTK2B | |
| SCHEMBL25590723 | 0.55 | KDM4E (0.47) | HTR3AKDM4EALDH1A1HRH4HRH3 | |
| SCHEMBL30309965 | 0.55 | KDM4E (0.47) | ADRA2CKDM4EGAAMAPTPTK2B | |
| SCHEMBL12845203 | 0.54 | RAB9A (0.57) | HTR3AKDM4EGAAMAPTALDH1A1 | |
| SCHEMBL13490012 | 0.54 | HTR3A (0.62) | HTR3AKDM4EALDH1A1HRH4HRH3 | |
| SCHEMBL29150947 | 0.54 | ADRA2C (0.44) | HTR3AADRA2CKDM4EGAAMAPT | |
| SCHEMBL14869922 | 0.54 | POLB (0.35) | HTT | |
| SCHEMBL29339678 | 0.54 | HTR3A (0.46) | HTR3AADRA2CKDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985745-B2 | Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor | ABBOTT LABORATORIES (US) | 2011-07-26 | — | — | US | disclosed |
| US-20080194538-A1 | Method for Pain Treatment | ABBVIE INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194538-A1 | Method for Pain Treatment | HRH4, HRH3, HRH2 | HTR3A 86/4885ADRA2C 171/4885KDM4E 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.